Clinicopathological significance of ALDH1A1 in lung, colorectal, and breast cancers: a meta-analysis. (August 2015)

• Record Type: Journal Article
• Authors: Zhou, Yang; Wang, Yixun; Ju, Xinxin; Lan, Jiaojiao; Zou, Hong; Li, Shugang; Qi, Yan; Jia, Wei; Hu, Jianming; Liang, Weihua; Zhang, Wenjie; Pang, Lijuan; Li, Feng
• Is Part Of: Biomarkers in medicine. Volume 9:Number 8(2015)
• Page Start: 777
• Page End: 790
• Publication Date: 2015-08
• Subjects: aldehyde dehydrogenase 1A1 -- breast cancer -- cancer stem cell -- colorectal cancer -- lung cancer; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/BMM.15.49
• Languages: English
• ISSNs: 1752-0363

Abstract

Aim: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is a putative cancer stem cell marker. This meta-analysis evaluated ALDH1A1 expression's clinicopathological associations with lung cancer (LC), colorectal cancer (CRC) and breast cancer (BC).Materials & methods: Publications were retrieved from various databases and assessed for relevance and quality. Relationships between ALDH1A1 expression and clinicopathological characteristics were evaluated using Review Manager 5.2 software.Results: Thirty-eight studies were included (6057 patients). ALDH1A1 expression was significantly associated with the presence of LC; lymph node metastasis, clinical stage and differentiation in LC and BC; and molecular subtype in BC (p < 0.05). There were no significant association with BC tumor size and CRC.Conclusion: ALDH1A1 may be a stem cell marker in LC and BC.